Evaluation of the monocyte activation test for the safety testing of meningococcal B vaccine Bexsero: A collaborative study

• Published in: Vaccine 2019-06, Vol.37 (29), p.3761-3769
• Main Authors: Studholme, Lucy, Sutherland, Janet, Desai, Trusha, Hockley, Jason, Care, Rory, Nordgren, Ida Karin, Vipond, Caroline
• Format: Article
• Language: English
• Subjects: Bexsero; Blood donors; Cell activation; Collaboration; Confidence limits; Cytokines; Fever; Immune system; Laboratories; Meningococcal vaccine; Monocyte activation test; Monocytes; Outer membrane vesicles; Pharmacology; Pyrogenicity; Pyrogens; Rabbit pyrogen test; Rabbits; Vaccines; Validity
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2018.05.073

•Quantification of pyrogenic content of a meningococcal B vaccine using the MAT.•Application of Ph. Eur. Chapter 2.6.30 Method C: Reference Lot Comparison Test.•Collaborative study with 9 participating laboratories, testing 3 batches of vaccine.•Consistency and accuracy of MAT results notable given the range of test systems.•Supports replacement of the RPT with the MAT for intrinsically pyrogenic products. The aim of this collaborative study was to evaluate the robustness of the monocyte activation test (MAT) for quantifying the pyrogenic content in the outer membrane vesicle (OMV)-containing vaccine Bexsero: the first meningococcal B vaccine to be licenced. We analysed datasets from 9 laboratories covering 15 test systems for 3 batches of Bexsero with higher, equivalent and lower activity relative to a reference lot in the MAT. Activity was measured in terms of relative pyrogen units (RPU) based on European Pharmacopoeia (Ph. Eur.) MAT Chapter 2.6.30 Method C: Reference Lot Comparison Test. We report that all 15 test systems were consistent in that they showed sample A to be the most active in the MAT; that 13 of 15 test systems had an accuracy of more than 80% and an overall geometric mean RPU of 1.03 with lower and upper 95% confidence limits of 0.97 and 1.09 respectively for a sample with an expected value of 1.00 RPU. We also report larger variability in the results for test systems involving cells from individual blood donations for sample A suggesting that there could be donor to donor differences in sensitivity to the vaccine constituents responsible for the higher activity of this batch. Overall, the consistency and accuracy of the MAT was remarkable given the range of test systems used by participants, all of which are permitted by the Ph. Eur. General MAT Chapter. This is important given the limitations of the rabbit pyrogen test for the control of pyrogenicity in general and particularly with products with intrinsic pyrogenicity such as Bexsero.